Regencell Bioscience (RGC) CBO reports 581,514-share stake

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd Chief Business Officer Au Yat-Pui filed a Form 3 reporting beneficial ownership of 581,514 ordinary shares held directly. The filing is an ownership disclosure and does not report any new share purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

AU YAT-PUI

(Last) (First) (Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value $0.00001	581,514	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Wai Hong Chung, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Regencell Bioscience (RGC) Form 3 filing show?

The Form 3 shows that Chief Business Officer Au Yat-Pui beneficially owns 581,514 ordinary shares of Regencell Bioscience Holdings Ltd. It is an ownership disclosure and does not indicate any recent purchases or sales.

How many Regencell Bioscience (RGC) shares does Au Yat-Pui report owning?

Au Yat-Pui reports beneficial ownership of 581,514 ordinary shares of Regencell Bioscience Holdings Ltd. These shares are listed as directly owned in the Form 3 filing, with no associated transaction price or trade details disclosed.

Does the Regencell (RGC) Form 3 indicate insider buying or selling?

No, the Form 3 does not indicate insider buying or selling. It reports a holding entry showing 581,514 ordinary shares owned directly by Au Yat-Pui, with no transaction code, trade date pricing, or share purchase or sale amounts disclosed.

What role does the reporting person hold at Regencell Bioscience (RGC)?

The reporting person, Au Yat-Pui, is identified as the Chief Business Officer of Regencell Bioscience Holdings Ltd. The Form 3 links this officer role to direct beneficial ownership of 581,514 ordinary shares in the company.

Are the Regencell (RGC) shares in the Form 3 held directly or indirectly?

The Form 3 shows the 581,514 ordinary shares as directly owned by Au Yat-Pui. The ownership code is marked “D” for direct, and no trusts, entities, or indirect ownership structures are referenced in the provided data.